Putnam, leading scientific and strategic consulting partner, is thrilled to announce Scott Briggs and Thomas Marder have been promoted to Partner. The firm congratulates Scott and Thomas on this incredible achievement.
Scott first joined Putnam as an Associate Consultant in 2014 after completing his undergraduate degree in Biology at Duke University. After four years at Putnam, he took a brief hiatus from the firm to pursue an MBA from Harvard Business School, where he graduated with High Distinction as a Baker Scholar. Since rejoining Putnam in 2020, Scott has become a leader in Putnam’s Value, Pricing, & Access (VPA) Practice Area, where he advises both large biopharma and emerging biotech companies on a range of topics including product value demonstration and communication, pricing and contracting strategy, payer and policymaker engagement strategy, and integration of access-related considerations into pipeline decision-making. In addition, Scott regularly supports his clients with commercial strategy decision-making including new product development strategy, forecasting, positioning, and lifecycle management strategy, leveraging his prior experience working in drug discovery at Ionis Pharmaceuticals and pipeline commercialization at BioMarin Pharmaceuticals.
Scott is a role model for Putnam’s consultants, embodying determination and a commitment to excellence. When asked what he is most excited for as Partner, he cites the opportunity to help chart Putnam’s future path including expansion of our integrated service offerings, underscored by Putnam’s mission to help clients solve the most complex and challenging problems. He adds, “Most importantly, I’m looking forward to mentoring the next generation of Putnam leaders and fostering the supportive, inclusive, and close-knit culture that has been integral to my growth at Putnam and our growth as an organization over the last ten years.”
Thomas has been with Putnam since 2014 and is Putnam’s only team member to have worked stints in three different offices – Boston, San Francisco, and New York. In his ten years at Putnam, Thomas has cultivated expertise across the industry’s most active disease areas, including oncology, where most of his work focuses, hematology, and immunology. He currently splits time across Putnam’s Commercial and Value, Pricing, & Access (VPA) practices – specializing in both new product planning and US-focused market access strategy – and finds that these complementary skillsets allow his clients to benefit from cross-pollination of insights across functional areas.
Thomas joined Putnam from the Joslin Diabetes Center, where he conducted clinical neuroscience research focused on patients with Type 2 diabetes and first developed a passion for the intersection of science and business. He holds an MBA in Health Care Management from the Wharton School and a BA in Neuroscience from Dartmouth College.
As a Partner at Putnam, Thomas looks forward to continuing to build the firm’s offerings related to the Inflation Reduction Act – including support for CMS negotiations, payer contracting, and portfolio strategy. He is also excited to continue fostering Putnam’s unique culture and supporting the growth of Putnam’s next generation of leadership through mentorship. When asked what advice he would give to Putnam’s future leaders, Thomas adds “Don’t ever get too comfortable. Without taking on work that’s outside of your comfort zone, you’ll never learn new things!”
Please join the firm in congratulating Scott and Thomas.
About Putnam
Putnam is a leading scientific and strategic consulting partner that helps the global life science community make confident decisions, build value, and bring life-changing innovations to clinicians and patients. For over 30 years, our rigorous, bespoke approach and globally diverse team have maximized the human impact and commercial success of client innovations.
